异动解读 | 科济药业-B盘中大跌6.63% 旗舰CAR-T产品未入新医保目录引发担忧

异动解读
28 Nov 2024

科济药业-B(02171)今日盘中大跌6.63%,引发市场广泛关注。

公开消息显示,2024年新版国家医保目录出炉,但科济药业旗舰CAR-T细胞疗法泽沃基奥仑赛注射液等4款百万元级重磅产品未能进入目录。该消息可能引发投资者担忧该公司未来销售前景,导致股价大幅下跌。

科济药业是一家主攻CAR-T细胞免疫疗法的创新生物技术公司,泽沃基奥仑赛注射液作为其主打产品,未能纳入新版医保目录可能会对公司收入及盈利能力产生一定影响。市场投资者对此保持谨慎观望态度,推动股价出现大幅波动。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10